Q1 EPS Estimates for iTeos Therapeutics Increased by Wedbush

iTeos Therapeutics, Inc. (NASDAQ:ITOS) – Wedbush increased their Q1 2025 EPS estimates for shares of iTeos Therapeutics in a note issued to investors on Wednesday, March 5th. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.68) per share for the quarter, up from their prior estimate of ($0.79). Wedbush currently has a “Outperform” rating and a $25.00 target price on the stock. The consensus estimate for iTeos Therapeutics’ current full-year earnings is ($3.49) per share. Wedbush also issued estimates for iTeos Therapeutics’ Q2 2025 earnings at ($0.80) EPS, Q3 2025 earnings at ($0.77) EPS, Q4 2025 earnings at ($0.83) EPS, FY2025 earnings at ($3.09) EPS, FY2026 earnings at ($3.95) EPS, FY2027 earnings at ($4.63) EPS and FY2028 earnings at ($4.32) EPS.

Other research analysts have also recently issued reports about the stock. JPMorgan Chase & Co. lowered their price target on shares of iTeos Therapeutics from $22.00 to $15.00 and set an “overweight” rating on the stock in a report on Thursday, March 6th. Wells Fargo & Company lowered their price target on shares of iTeos Therapeutics from $19.00 to $17.00 and set an “overweight” rating on the stock in a report on Thursday, March 6th. Finally, HC Wainwright reissued a “buy” rating and issued a $46.00 price target on shares of iTeos Therapeutics in a report on Thursday, March 6th.

iTeos Therapeutics Stock Performance

Shares of ITOS stock opened at $7.06 on Monday. The firm’s 50-day moving average is $7.51 and its 200-day moving average is $9.22. The stock has a market cap of $269.65 million, a price-to-earnings ratio of -2.24 and a beta of 1.38. iTeos Therapeutics has a 52-week low of $6.67 and a 52-week high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last issued its earnings results on Wednesday, March 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.13.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Point72 DIFC Ltd acquired a new position in shares of iTeos Therapeutics during the 3rd quarter worth approximately $31,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of iTeos Therapeutics during the 4th quarter worth approximately $42,000. Virtus ETF Advisers LLC grew its position in shares of iTeos Therapeutics by 58.2% during the 4th quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company’s stock worth $69,000 after purchasing an additional 3,293 shares in the last quarter. Forefront Analytics LLC acquired a new position in shares of iTeos Therapeutics during the 4th quarter worth approximately $85,000. Finally, Graham Capital Management L.P. acquired a new position in shares of iTeos Therapeutics during the 4th quarter worth approximately $85,000. Institutional investors and hedge funds own 97.16% of the company’s stock.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.